SLNO - NASDAQ

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%

HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.76B

EPS0.4100

P/E Ratio117.86

Earnings Date08/05/2026

563.83M

Assets

70%

3Y+2028.0%

5Y+768.0%

10Y+10032.0%

113.72M

Total Liabilities

32%

3Y+604.0%

5Y+485.0%

10Y+5240.0%

450.12M

Total Equity

84%

3Y+4250.0%

5Y+888.0%

10Y+13003.0%

Soleno Therapeutics, Inc. Funding & Solvency Profile

SLNO · NASDAQ

Current Assets

Cash & Cash Equivalents70.11M

Net Receivables28.21M

Inventory15.02M

Other Current Assets7.11M

Total Current Assets356 M

Non-Current Assets

Property, Plant & Equipment2.38M

Goodwill & Intangible Assets4.86M

Long-Term Investments0.00

Other Non-Current Assets200.78M

Total Non-Current Assets203 M

Total Assets

563.83M

Financial Health Analysis

Current Ratio

5.80x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.25x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

294 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

63% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Soleno Therapeutics, Inc. Balance Sheet

SLNO • NASDAQ

Soleno Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	70.1M	87.9M	169.7M	14.6M	21.3M	49.2M	20.7M	23.1M	17.1M	2.7M	5.5M	8M	1.3M	2.2M
Short-Term Investments	235.4M	203.5M	0.0	0.0	0.0	0.0	0.0	978K	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	305.5M	291.4M	169.7M	14.6M	21.3M	49.2M	20.7M	24.1M	17.1M	2.7M	5.5M	8M	1.3M	2.2M
Net Receivables	28.2M	0.0	0.0	0.0	0.0	0.0	0.0	64K	0.0	133.3K	156.1K	0.0	149.6K	150.8K
Accounts Receivables	28.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	133.3K	156.1K	0.0	149.6K	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64K	0.0	0.0	0.0	0.0	0.0	150.8K
Inventory	15M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	660.4K	551K	109.3K	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	1.1M	1M	411K	529K	343K	246.6K	167.6K	252.3K	85.1K	61.5K
Other Current Assets	7.1M	2.5M	1.7M	1M	0.0	0.0	0.0	0.0	551K	695.4K	35K	20K	20K	20K
Total Current Assets	355.8M	293.9M	171.4M	15.6M	22.4M	50.2M	21.1M	24.7M	18M	3.8M	6.4M	8.3M	1.5M	2.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.4M	3M	419K	157K	454K	158K	444K	12K	22.9K	102.6K	85.7K	57.6K	63.2K	105.5K
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	125.5K	718K	718K	0.0	0.0	0.0
Intangible Assets	4.9M	6.8M	8.7M	10.7M	12.6M	14.6M	16.5M	18.5M	20.4M	817.5K	916.8K	0.0	0.0	0.0
Goodwill & Intangible Assets	4.9M	6.8M	8.7M	10.7M	12.6M	14.6M	16.5M	18.5M	20.5M	1.5M	1.6M	0.0	0.0	0.0
Long-Term Investments	0.0	27.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	200.8M	83K	165K	0.0	40K	0.0	59K	0.0	591.9K	125.5K	76.3K	0.0	0.0	21.1K
Total Non-Current Assets	208M	37.1M	9.3M	10.9M	13.1M	14.7M	17M	18.5M	21M	1.8M	1.8M	57.6K	63.2K	126.5K
Total Assets	563.8M	331M	180.7M	26.5M	35.6M	65M	38.2M	43.2M	39M	5.6M	8.2M	8.4M	1.6M	2.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	12.4M	8.9M	3.1M	1.8M	3.3M	3.5M	2M	934K	633K	410.5K	495.3K	986.8K	57.7K	219.5K
Accounts Payable	12.4M	8.9M	3.1M	1.8M	3.3M	3.5M	2M	934K	633K	410.5K	495.3K	986.8K	57.7K	219.5K
Accrued Expenses	0.0	0.0	3.1M	3.2M	3.4M	3.8M	2M	320K	973K	1.1M	516K	201.5K	128.7K	191K
Short Term Debt	726K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	101.5K	14M	11.1M
Capital Lease Obligations (Current)	0.0	526K	273K	155K	282K	139K	305K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-14M	-11.1M
Other Current Liabilities	48.2M	9.3M	4.9M	2.2M	1.1M	1.2M	665K	623K	127K	246.4K	2.2M	0.0	0.0	0.0
Total Current Liabilities	61.4M	18.7M	11.5M	7.3M	8M	8.6M	5M	1.9M	1.7M	1.7M	3.2M	1.3M	14.2M	11.5M
NON-CURRENT LIABILITIES
Long Term Debt	2M	49.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5M	1.4M
Other Non-Current Liabilities	50.4M	14.8M	11.5M	8.8M	9.6M	10.8M	18.3M	10.9M	10.5M	422.3K	1.8M	17.4M	23.8M	23.8M
Total Non-Current Liabilities	52.4M	67.1M	11.7M	8.8M	9.8M	10.8M	18.3M	10.9M	10.8M	422.3K	1.8M	17.4M	25.3M	25.2M
Capital Lease Obligations	0.0	3M	403K	155K	457K	139K	305K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	113.7M	85.9M	23.2M	16.1M	17.8M	19.4M	23.2M	12.7M	12.5M	2.1M	5M	18.7M	39.5M	36.7M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	13.0	5.0	0.0	25.3M	25.2K
Common Stock	52K	46K	32K	8K	80K	80K	45K	32K	19.2K	16.8K	14K	6.8K	536.0	522.0
Additional Paid-In Capital	0.0	697M	433.9M	247.8M	231.1M	227.9M	172.7M	157.4M	140.5M	101.7M	89.5M	60.6M	19.2M	19.2M
Retained Earnings	-431.4M	-452.3M	-276.4M	-237.4M	-213.4M	-182.4M	-157.8M	-127M	-114M	-98.3M	-86.2M	-71M	-57.1M	-53.4M
Accumulated Other Comprehensive Income/Loss	415K	361K	0.0	0.0	0.0	0.0	0.0	-93K	-73.6K	-159.4K	-211.9K	-144.8K	-155.4K	-216.2K
Other Total Stockholders' Equity	881M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-857.4K	24M	24M
Total Stockholders' Equity	450.1M	245.1M	157.5M	10.3M	17.8M	45.5M	14.9M	30.4M	26.5M	3.4M	3.2M	-10.3M	-37.9M	-34.2M
Total Equity	450.1M	245.1M	157.5M	10.3M	17.8M	45.5M	14.9M	30.4M	26.5M	3.4M	3.2M	-10.3M	-37.9M	-34.2M
SUMMARY
Total Liabilities & Equity	563.8M	331M	180.7M	26.5M	35.6M	65M	38.2M	43.2M	39M	5.6M	8.2M	8.4M	1.6M	2.5M
Total Investments	235.4M	230.7M	0.0	0.0	0.0	0.0	0.0	978K	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	2.7M	52.8M	403K	155K	457K	139K	305K	0.0	0.0	0.0	0.0	101.5K	14M	11.1M
Net Debt	-67.4M	-35.1M	-169.3M	-14.4M	-20.8M	-49.1M	-20.4M	-23.1M	-17.1M	-2.7M	-5.5M	-7.9M	12.7M	9M
Shares Outstanding	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025	53,710,025

SEC Filings

SLNO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	April 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 23, 2026	January 21, 2026	2026	View Filing

Showing 1 to 10 of 262 filings

Related Guides

Blog Categories

Continue your SLNO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.